18 results
8-K
EX-99.1
UBX
Unity Biotechnology Inc
16 Sep 20
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
4:49pm
of aging.
Revised Financial Guidance
UNITY will reduce its workforce by approximately 30% to optimize capital allocation and align with key strategic … of UBX1325 in diabetic macular edema, the expected size of UNITY’s workforce following the restructuring, the impact of the workforce reduction
8-K
UBX
Unity Biotechnology Inc
16 Sep 20
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
4:49pm
will result in an elimination of approximately 30 positions, or approximately 30% of the Company’s workforce, by the end of the year. The Company estimates … the its restructuring plan; its expectations and estimates regarding the workforce reduction; the objectives of the restructuring plan and the timing
8-K
UBX
Unity Biotechnology Inc
3 Feb 22
UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs
4:06pm
-2022. The Restructuring will result in an elimination of approximately half of the Company’s workforce, reducing its staff to 34 full-time employees
8-K
EX-99.1
UBX
Unity Biotechnology Inc
3 Feb 22
UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs
4:06pm
. UNITY will reduce its workforce, primarily in Discovery Research, by approximately 50% in order to optimize capital allocation and align with key
10-K
EX-10.23
92ruvzvq 230n6ot7w8p
6 Mar 19
Annual report
8:06am
- Prev
- 1
- Next